A Fullerene−Paclitaxel Chemotherapeutic: Synthesis, Characterization, and Study of Biological Activity in Tissue Culture
Journal of the American Chemical Society2005Vol. 127(36), pp. 12508–12509
Citations Over TimeTop 10% of 2005 papers
Tatiana Y. Zakharian, Alexander Seryshev, Balaji Sitharaman, Brian E. Gilbert, Vernon Knight, Lon J. Wilson
Abstract
A fullerene-paclitaxel conjugate has been synthesized as a slow-release drug for aerosol liposome delivery of paclitaxel for lung cancer therapy. The conjugate was designed to release paclitaxel via enzymatic hydrolysis and subsequently has shown a half-life of release of 80 min in bovine plasma. A liposome formulation of the conjugate has been prepared using dilauroylphosphatidylcholine (DLPC), and its IC50 is virtually identical to the IC50 for a paclitaxel-DLPC formulation in human epithelial lung carcinoma A549 cells. With both clinically relevant kinetics of hydrolysis and significant cytotoxicity in tissue culture, the conjugate holds promise for enhanced therapeutic efficacy of paclitaxel in vivo.
Related Papers
- → Pharmacologic Sensitivity of Paclitaxel to Its Delivery Vehicles Drives Distinct Clinical Outcomes of Paclitaxel Formulations(2015)44 cited
- → Effect of liposome type and membrane fluidity on drug–membrane partitioning analyzed by immobilized liposome chromatography(2001)68 cited
- → Complement Dependent and Independent Liposome Uptake by Peritoneal Macrophages: Cholesterol Content Dependency.(1998)17 cited
- Pharmacokinetics of paclitaxel in a hemodialysis patient with advanced gastric cancer： A case report(2006)
- Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients(2006)